
A number of Lundbeck’s drugs are generating more profit than the Danish company expected them to. The extra money set to make it onto Lundbeck’s top line sees the Danish group raising its expectations for annual turnover to DKK 14.8-15.2bn (USD 2.7-2.75bn) from the previous guidance of DKK 14.6-15.0bn (USD 2.65-2.72bn).
According to CFO Anders Gotzsche, Lundbeck’s drugs are generally performing well at the moment, but four products really stand out.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app